-
CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2023
20240328 -
CANbridge and PUMCH announced the establishment of PUMCH- CANbridge Genetic Defect Rare Disease Innovation and Translation Base
20240301 -
Livmarli mentioned as a case study The Policy Address highlights Hong Kong's strengths in research and development, emphasizing its capcity to independently approve new drugs Rare disease drugs will receive significant benefits
20231115 -
Foundation consolidated over time and for a rosy future | 2023 China Conference on Rare Diseases closed successfully
20231106 -
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress
20231025 -
CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China’s National Medical Products Administration
20231017 -
CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China
20231016 -
CANbridge Announces Marketing Approval of CAN108 (邁芮倍®/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)
- LIVMARLI is the First and Only Treatment Approved in Taiwan for Cholestatic Pruritus in ALGS
- LIVMARLI is approved for Cholestatic Pruritus in ALGS in the US, Canada, Europe, Mainland China, and other regions globally
20231009 -
CANbridge Announces Marketing Approval of CAN108 (LIVMARLI®) in Hong Kong for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)
- LIVMARLI is the First and Only Treatment Approved in Hong Kong for Cholestatic Pruritus in ALGS
- LIVMARLI is approved for Cholestatic Pruritus in ALGS in the United States, Canada, Europe, Mainland China and other regions globally
2023092801
Media Reports
Press Release